Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised EU Guide Addresses Ambiguities In Reporting of Safety Info From Trials

Executive Summary

The pharmaceutical industry is hoping that changes to the EU guideline on the management and presentation of reference safety information (RSI) in clinical trial applications will help companies struggling with new regulatory focus on this complex subject.


Related Content

Un-blinding, Pharmacovigilance Issues Among Top GCP Findings, Says UK Inspector
EU Guide To Tackle Inconsistent Reporting Of Reference Safety Info In Trials
Solving The Trial Safety Information Puzzle: Regulators And Industry Pitch In
UK MHRA Takes Companies To Task Over Trial Safety Information Reporting





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts